Am J Transplant, Volume 20, Suppl 3 Archives - Page 211 of 223 - ATC Abstracts

2020 American Transplant Congress
Factors Associated with Renal Graft Loss in Simultaneous Kidney-Heart Transplant Recipients in the UNOS Cohort
K. A. Agarwal¹, H. Patel¹, K. Almonte², F. Cardarelli¹, N. Agrawal¹
¹Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, ²Medicine, Mount Auburn Hospital, Cambridge, MA
*Purpose: Simultaneous kidney and heart transplants (SKHT) are employed for patients with both end-stage heart failure and severely impaired kidney function. Renal outcomes in such…
2020 American Transplant Congress
High Frequencies of Donor-Derived Memory T and NK Cells in the Blood of Lung Transplant Recipients May Contribute to Protection from Chronic Lung Allograft Dysfunction
R. Bellmàs Sanz¹, A. Hitz¹, B. Wiegmann², K. Bläsing¹, F. Ius², W. Sommer², J. Kühne¹, L. Horn¹, A. Knöfel², I. Tudorache², A. Haverich², D. Jonigk³, G. Warnecke², C. Falk¹
¹Institute of Transplant Immunology, Hannover Medical School MHH, Hannover, Germany, ²Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School MHH, Hannover, Germany, ³Institute of Pathology, Hannover Medical School MHH, Hannover, Germany
*Purpose: After lung transplantation (LuTx), a transient chimerism of donor cells exists in the blood of recipients due to the migration of lymphocytes from the…
2020 American Transplant Congress
Increasing Utilization via Accelerating the Placement of Hard-to-Place Kidneys
S. Noreen¹, R. Brown¹, Y. Becker², M. Cooper³, K. O'Connor⁴, J. Prinz⁵, D. Klassen¹
¹United Network for Organ Sharing, Richmond, VA, ²University of Chicago Medical Center, Chicago, IL, ³MedStar Georgetown Transplant Institute, Washington, DC, ⁴LifeCenter Northwest, Bellevue, WA, ⁵Donor Alliance, Denver, CO
*Purpose: Increasing the number of transplants by increasing utilization is a key goal of the OPTN, with a particular focus on the use of marginal…
2020 American Transplant Congress
Graft Survival after Liver Transplantation for Patients with Cholangiocarcinoma
I. A. Ziogas, L. A. Hickman, L. K. Matsuoka, M. I. Montenovo, M. Izzy, S. A. Rega, I. D. Feurer, S. P. Alexopoulos
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Liver transplantation (LT) with neoadjuvant chemoradiation is increasingly utilized for the treatment for unresectable cholangiocarcinoma (CCA), however, post-LT graft survival is not well described.…
2020 American Transplant Congress
Modelling Patient Outcomes after Listing for Deceased Donor Kidney Transplantation in the UK: A Novel Technique
M. Ibrahim¹, L. Mumford¹, R. Hogg¹, R. Johnson¹, M. Pearson², J. Forsythe³, C. Callaghan⁴
¹Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom, ²Winton Centre for Risk Evidence and Communication, Cambridge, United Kingdom, ³NHS Blood and Transplant, Bristol, United Kingdom, ⁴Renal, Guy's and St Thomas' NHS Trust, London, United Kingdom
*Purpose: Novel methods of data analysis and communication are needed to aid clinician and patient understanding of clinical outcomes. We aimed to demonstrate patient outcomes…
2020 American Transplant Congress
Longer-Term Outcomes from the THINKER and EXPANDER Trials of Transplantation Using HCV-Viremic Kidneys
V. S. Potluri¹, F. Naqvi², P. Reese¹, M. Shah¹, D. Brown², S. Prenner¹, A. Loupy³, A. Woodards¹, P. Abt¹, E. Blumberg¹, J. Trofe-Clark¹, D. Segev², R. Bloom¹, D. Sawinski¹, C. Durand², P. Porrett¹, M. Levine¹, D. Goldberg⁴, N. Desai²
¹University of Pennsylvania, Philadelphia, PA, ²Johns Hopkins, Baltimore, MD, ³Paris Transplant Group, Paris, France, ⁴University of Miami, Miami, FL
*Purpose: The practice of transplanting HCV-viremic kidneys into HCV-negative recipients has become more common, but longer-term outcomes have not been reported. We present data on…
2020 American Transplant Congress
Successful Heart Utilization and Outcomes with Long-Distance Transport of Deceased Donor Hearts: One Large Organ Procurement Organization’s Five-Year Experience
D. Adorno, C. Wells, K. O'Connor
LifeCenter Northwest, Bellevue, WA
*Purpose: Long-distance transport of deceased donor hearts has been associated with reduced organ utilization rates and risk of inferior outcomes. One U.S. Organ Procurement Organization’s…
2020 American Transplant Congress
Suppressing Laminin Alpha5 Creates Tolerogenic Niches for Allograft Survival
L. Li¹, M. Shirkey¹, W. Piao¹, Y. Xiong¹, V. Saxena¹, T. Zhang¹, C. Paluskievicz¹, J. Zhao², R. Abdi², J. S. Bromberg¹
¹UMB, Baltimore, MD, ²Harvard University, Boston, MA
*Purpose: Laminin α5 (Lama5) regulates CD4 T cell migration and function. We hypothesized that stromal Lama5 regulates the structure of the lymph node (LN) microenvironment…
2020 American Transplant Congress
Interim Experience in a Phase 3 Prospective, Randomized, Multi-Center, Open-Label, Controlled Trial of Cellular Immunotherapy with MDR-101 for Induction of Immune Tolerance in Recipients of HLA-Matched, Living Donor Kidney Transplants
D. Kaufman¹, J. Piper², M. Stegall³, S. Akkina⁴, E. Marin⁵, A. Gaber⁶, Y. Qasi⁷, T. Srinivas⁸, D. Alonso⁹, A. Patel¹⁰, M. Laftavi¹¹, A. Shah¹², S. Collette¹³, E. Stites¹⁴, K. Chavin⁸, S. Crowley¹⁵
¹UW, Madison, WI, ²INOVA, Fairfax, VA, ³Mayo, Rochester, MN, ⁴LUMC, Chicago, IL, ⁵Yale, New Haven, CT, ⁶Houston Methodist, Houston, TX, ⁷USC, Los Angeles, CA, ⁸UH Cleveland, Cleveland, OH, ⁹Intermountain, Murray, UT, ¹⁰SBMC, Livingston, NJ, ¹¹UH Upstate, Syracuse, NY, ¹²TJU, Philadelphia, PA, ¹³CIUSSS, Montreal, QC, Canada, ¹⁴UCH, Denver, CO, ¹⁵Medeor, San Francisco, CA
*Purpose: The goals of tolerance in patients with kidney transplants (KTxp) are to eliminate the lifelong need for immunosuppressive drugs (IS) and to prevent graft…
2020 American Transplant Congress
Benefits of Normothermia Regional Perfusion (NRP), Hypothermic Machine Perfusion (HMP) and Short Cold Ischemia Time (CIT) for Kidney Transplants with Controlled Donation after Circulatory Death (cDCD)
E. Savoye¹, C. Legeai¹, J. Branchereau², S. Gay³, S. Drouin⁴, F. Gaudez⁵, B. Veber⁶, J. Venhard⁷, G. Cheisson⁸, T. Kerforne⁹, O. Bastien¹, C. Antoine¹
¹Agence de la Biomedecine, La Plaine Saint Denis, France, ²CHU Nantes, Nantes, France, ³CH Annecy, Annecy, France, ⁴CHU Pitié Salpetriere, Paris, France, ⁵CHU Saint Louis, Paris, France, ⁶CHU Rouen, Rouen, France, ⁷CHU Tours, Tours, France, ⁸CHU Kremlin-Bicetre, Kremlin-Bicetre, France, ⁹CHU Poitiers, Poitiers, France
*Purpose: cDCD are considered as extended criteria donors with poorer kidney transplant outcomes and high delayed graft function (DGF) rate. We built a French national…